Matterworks

Matterworks is a private, early-stage biotech company leveraging artificial intelligence to transform biological research from an empirical to a predictive science. Its core offering is the Pyxis cloud platform, which applies large spectral models (LSMs) to raw mass spectrometry data for untargeted biochemical annotation and phenotype prediction. The company targets critical pain points in the life sciences R&D pipeline—from target discovery to clinical development and biomanufacturing—by providing explanatory power that sequence-based omics alone cannot deliver. Founded in 2020, Matterworks appears to be in an early commercial or pre-revenue phase, offering both self-service and enterprise-tier access to its AI predictive biologist.

Pyxis: A cloud-based AI platform featuring Large Spectral Models (LSMs) trained on billions of molecular spectra. It performs untargeted biochemical annotation and direct phenotype prediction from raw mass spectrometry (MS2) data.

Matterworks competes in the crowded AI-for-drug-discovery and computational biology market. It differentiates by specializing in biochemical (non-genomic) omics analysis via its Large Spectral Model trained specifically on mass spectrometry data. Competitors range from broad cloud AI providers (e.g., Google Vertex AI) to bioinformatics software firms and startups focused on other omics data types or different AI approaches.